Whole-Body Positron Emission Tomography with 18F-Fluorodeoxyglucose/Magnetic Resonance Imaging as a Screening Tool for the Detection of Malignant Transformation in Individuals with Neurofibromatosis Type 1

被引：2

作者：

Fertitta, Laura ^{[1
,2
,3
]}

Jannic, Arnaud ^{[1
,3
]}

Zehou, Ouidad ^{[1
]}

Bergqvist, Christina ^{[1
]}

Ferkal, Salah ^{[1
,3
]}

Moryousef, Sabine ^{[1
]}

Lerman, Lionel ^{[5
]}

Mule, Sebastien ^{[6
,7
]}

Luciani, Alain ^{[6
,7
]}

Bapst, Blanche ^{[8
]}

Ezzedine, Khaled ^{[1
,3
,7
]}

Ortonne, Nicolas ^{[2
,4
,7
]}

Itti, Emmanuel ^{[5
,7
]}

Wolkenstein, Pierre ^{[1
,2
,3
,7
]}

机构：

[1] Henri Mondor Hosp, Assistance Publ Hop Paris AP HP, Natl Referral Ctr Neurofibromatoses CERENEF, Dept Dermatol, 1 Rue Gustave Eiffel, F-94000 Creteil, France

[2] INSERM U955, Creteil, France

[3] Henri Mondor Hosp, Assistance Publ Hop Paris AP HP, Ctr Invest Clin 1430, INSERM, Creteil, France

[4] Henri Mondor Hosp, Assistance Publ Hop Paris AP HP, Dept Pathol, Creteil, France

[5] Henri Mondor Hosp, Assistance Publ Hop Paris AP HP, Dept Nucl Med, Creteil, France

[6] Henri Mondor Hosp, Assistance Publ Hop Paris AP HP, Dept Radiol, Creteil, France

[7] Univ Paris Est Creteil UPEC, Creteil, France

[8] Henri Mondor Hosp, Assistance Publ Hop Paris AP HP, Dept Neuroradiol, Creteil, France

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2024年 / 144卷 / 08期

关键词：

F-18-FDG-PET/MRI; MPNST; Neurofibromatosis; 1; Sarcoma; Screening; NERVE SHEATH TUMORS; SOFT-TISSUE SARCOMAS; PREVALENCE; CANCER; PET/CT; MRI; MANAGEMENT; MORTALITY; PET/MRI; BENIGN;

D O I：

10.1016/j.jid.2024.01.028

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in patients with neurofibromatosis type 1. They can result from premalignant neurofibromas, including neurofibromas with atypia and atypical neurofibromatous neoplasms of uncertain biologic potential. Some phenotypic characteristics have been described as associated with their development. The aim of this study was to outline our use of wholebody positron emission tomography with F-18-fluorodeoxyglucose/magnetic resonance imaging in adults with neurofibromatosis type 1, especially in the screening of asymptomatic individuals with a higher risk of developing an MPNST, and to study its impact on neurofibroma classification (malignant vs premalignant) and MPNST staging over time. Individuals with neurofibromatosis type 1 who underwent a positron emission tomography with F-18-fluorodeoxyglucose/magnetic resonance imaging between 2017 and 2021 were included, analyzing separately the screened population. Maximum standard uptake value and diffusion-weighted imaging were assessed. Biopsy/surgery confirmed the diagnosis. In all, 345 positron emission tomography with F-18-fluorodeoxyglucose/magnetic resonance imaging were performed in 241 patients, including 149 asymptomatic (62%) but at-risk patients. Eight MPNSTs in 8 screened individuals (5%), 6 neurofibromas with atypia in 4 individuals (3%), and 29 atypical neurofibromatous neoplasms of uncertain biologic potential in 23 individuals (15%) were diagnosed. Over time, the proportion of grade 3 MPNST and the malignant/premalignant ratio in screened individuals significantly decreased (P 1/4 .03 and P < .001, respectively). This study emphasizes the diagnostic and screening performances of whole-body positron emission tomography with F-18-fluorodeoxyglucose/magnetic resonance imaging in adults with neurofibromatosis type 1.

引用

页码：1754 / 1761.e1

页数：9

共 49 条

[1] Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1
Ahlawat, Shivani
Blakeley, Jaishri O.
Rodriguez, Fausto J.
Fayad, Laura M.
[J]. NEUROLOGY, 2019, 93 (11) : E1076 - E1084
[2] Current whole-body MRI applications in the neurofibromatoses NF1, NF2, and schwannomatosis
Ahlawat, Shivani
Fayad, Laura M.
Khan, Muhammad Shayan
Bredella, Miriam A.
Harris, Gordon J.
Evans, D. Gareth
Farschtschi, Said
Jacobs, Michael A.
Chhabra, Avneesh
Salamon, Johannes M.
Wenzel, Ralph
Mautner, Victor F.
Dombi, Eva
Cai, Wenli
Plotkin, Scott R.
Blakeley, Jaishri O.
[J]. NEUROLOGY, 2016, 87 : S31 - S39
[3] Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2
Abaza, MM
Makariou, E
Armstrong, M
Lalwani, AK
[J]. LARYNGOSCOPE, 1996, 106 (06) : 694 - 699
[4] Correlation Between Glycolytic Phenotype and Tumor Grade in Soft-Tissue Sarcomas by 18F-FDG PET
Benz, Matthias R.
Dry, Sarah M.
Eilber, Fritz C.
Allen-Auerbach, Martin S.
Tap, William D.
Elashoff, David
Phelps, Michael E.
Czernin, Johannes
[J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (08) : 1174 - 1181
[5] Risk of cancer from diagnostic X-rays:: estimates for the UK and 14 other countries
Berrington de González, A
Darby, S
[J]. LANCET, 2004, 363 (9406) : 345 - 351
[6] Simultaneously Acquired MR/PET Images Compared with Sequential MR/PET and PET/CT: Alignment Quality
Brendle, Cornelia B.
Schmidt, Holger
Fleischer, Sabrina
Braeuning, Uli H.
Pfannenberg, Christina A.
Schwenzer, Nina F.
[J]. RADIOLOGY, 2013, 268 (01) : 190 - 199
[7] ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1
Carton, Charlotte
Evans, D. Gareth
Blanco, Ignacio
Friedrich, Reinhard E.
Ferner, Rosalie E.
Farschtschi, Said
Salvador, Hector
Azizi, Amedeo A.
Mautner, Victor
Roehl, Claas
Peltonen, Sirkku
Stivaros, Stavros
Legius, Eric
Oostenbrink, Rianne
[J]. ECLINICALMEDICINE, 2023, 56
[8] Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO
[9] 2-3
[10] Comparative Effectiveness of 18F-FDG PET/CT Versus Whole-Body MRI for Detection of Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
Derlin, Thorsten
Tornquist, Katharina
Muenster, Silvia
Apostolova, Ivayla
Hagel, Christian
Friedrich, Reinhard E.
Wedegaertner, Ulrike
Mautner, Victor F.
[J]. CLINICAL NUCLEAR MEDICINE, 2013, 38 (01) : E19 - E25

← 1 2 3 4 5 →